Patents by Inventor David Andrew Griffith

David Andrew Griffith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9145416
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: September 29, 2015
    Assignee: Pfizer Inc.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Patent number: 9139587
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Publication number: 20150112068
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 areas described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 23, 2015
    Applicant: PFIZER INC.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • Publication number: 20150011470
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Applicant: PFIZER INC.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Publication number: 20140323730
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • Patent number: 8859577
    Abstract: The invention provides a compound of Formula (I) Z N N O N O A1R2 R1 R3R 3 L A2 (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3,Z, A1, L and A 5 2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: October 14, 2014
    Assignee: Pfizer Inc.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Publication number: 20140288111
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: May 9, 2014
    Publication date: September 25, 2014
    Applicant: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Patent number: 8802690
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 12, 2014
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Patent number: 8802688
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: April 21, 2012
    Date of Patent: August 12, 2014
    Assignee: Pfizer Inc.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, Jr.
  • Publication number: 20130296319
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 7, 2013
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Patent number: 8507681
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: August 13, 2013
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Publication number: 20130190334
    Abstract: The invention provides a compound of Formula (I) Z N N O N O A1R2 R1 R3R 3 L A2 (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3,Z, A1, L and A 5 2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: September 20, 2011
    Publication date: July 25, 2013
    Applicant: PFIZER INC.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Publication number: 20120270893
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: April 21, 2012
    Publication date: October 25, 2012
    Applicant: PFIZER INC.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • Patent number: 8288405
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: October 16, 2012
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Publication number: 20120225900
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: October 28, 2010
    Publication date: September 6, 2012
    Applicant: PFIZER INC.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Publication number: 20110111046
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 12, 2011
    Inventors: SCOTT WILLIAM BAGLEY, DAVID ANDREW GRIFFITH, DANIEL WEI-SHUNG KUNG
  • Patent number: 6953791
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: October 11, 2005
    Assignee: Pfizer, Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Patent number: 6951850
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: October 4, 2005
    Assignee: Pfizer, Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Patent number: 6924280
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: August 2, 2005
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Patent number: RE38524
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: June 1, 2004
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker